Fadl-Elmula Imad
Al Neelain Medical Research Center, Faculty of Medicine, Al Neelain University, Khartoum, Sudan.
Cell Chromosome. 2005 Aug 7;4:1. doi: 10.1186/1475-9268-4-1.
This article reviews and summarizes chromosomal changes responsible for the initiation and progression of uroepithelial carcinomas. Characterization of these alterations may lead to a better understanding of the genetic mechanisms and open the door for molecular markers that can be used for better diagnosis and prognosis of the disease. Such information might even help in designing new therapeutic strategies geared towards prevention of tumor recurrences and more aggressive approach in progression-prone cases. The revision of 205 cases of uroepithelial carcinomas reported with abnormal karyotypes showed karyotypic profile characterized by nonrandom chromosomal aberrations varying from one or few changes in low-grade and early stage tumors to massively rearranged karyotypes in muscle invasive ones. In general, the karyotypic profile was dominated by losses of chromosomal material seen as loss of entire chromosome and/or deletions of genetic materials. Rearrangements of chromosome 9 resulting in loss of material from 9p, 9q, or of the entire chromosome were the most frequent cytogenetic alterations, seen in 45% of the cases. Whereas loss of material from chromosome arms 1p, 8p, and 11p, and gains of chromosome 7, and chromosome arm 1q, and 8q seem to be an early, but secondary, changes appearing in superficial and well differentiated tumors, the formation of an isochromosome for 5p and loss of material from 17p are associated with more aggressive tumor phenotypes. Upper urinary tract TCCs have identical karyotypic profile to that of bladder TCCs, indicating the same pathogenetic mechanisms are at work in both locales. Intratumor cytogenetic heterogeneity was not seen except in a few post-radiation uroepithelial carcinomas in which distinct karyotypic and clonal pattern were characterized by massive intratumor heterogeneity (cytogenetic polyclonality) with near-diploid clones and simple balanced and/or unbalanced translocations. In the vast majority of cases strong correlation between the tumors grade/stage and karyotypic complexity was seen, indicating that progressive accumulation of acquired genetic alterations is the driving force behind multistep bladder TCC carcinogenesis. Although most of these cytogenetic alterations have been identified for many years, the molecular consequences and relevant cancer genes of these alterations have not yet been identified. However, loss of TSG(s) from chromosome 9 seems to be the primary and important event(s) in uroepithelial carcinogenesis.
本文回顾并总结了导致尿路上皮癌发生和进展的染色体变化。对这些改变的特征描述可能有助于更好地理解其遗传机制,并为可用于该疾病更好诊断和预后的分子标志物打开大门。此类信息甚至可能有助于设计新的治疗策略,以预防肿瘤复发,并针对易进展病例采取更积极的治疗方法。对205例报告有核型异常的尿路上皮癌病例的回顾显示,核型特征表现为非随机染色体畸变,从低级别和早期肿瘤中的一种或几种改变到肌肉浸润性肿瘤中大量重排的核型不等。一般来说,核型特征以染色体物质的缺失为主,表现为整条染色体的丢失和/或遗传物质的缺失。导致9p、9q物质丢失或整条9号染色体丢失的9号染色体重排是最常见的细胞遗传学改变,见于45%的病例。而1p、8p和11p染色体臂物质的丢失,以及7号染色体、1q染色体臂和8q染色体臂的增加似乎是浅表性和高分化肿瘤中出现的早期但次要的改变,5p等臂染色体的形成和17p物质的丢失与更具侵袭性的肿瘤表型相关。上尿路移行细胞癌与膀胱移行细胞癌具有相同的核型特征,表明相同的致病机制在这两个部位都起作用。除了少数放射后尿路上皮癌外,未观察到肿瘤内细胞遗传学异质性,在这些放射后尿路上皮癌中,明显的核型和克隆模式表现为肿瘤内大量异质性(细胞遗传学多克隆性),伴有近二倍体克隆以及简单的平衡和/或不平衡易位。在绝大多数病例中,肿瘤分级/分期与核型复杂性之间存在强烈相关性,表明获得性基因改变的逐步积累是膀胱移行细胞癌多步骤致癌过程背后的驱动力。尽管其中大多数细胞遗传学改变已被识别多年,但这些改变的分子后果和相关癌基因尚未确定。然而,9号染色体上肿瘤抑制基因的丢失似乎是尿路上皮癌发生过程中的主要和重要事件。